Common bacteria modified to make designer sugar-based drug

The ability to have genes be implemented in E.coli and reproduce essential compounds to be utilized in pharmaceuticals will drastically disrupt the medical industry at a large scale that relies on animal derivatives. The pain point is creating enzymes that catalyze these reactions to create the necessary molecules with algorithms and engineering, that multidisciplanary approaches within engineering and biosciences may be necessary to progress the future of sciences. The most novel discoveries of synthesis are the chondroitini sulfate to treat arthritis derived from cow trachea and heparin, a blood thinning medicine derived from pig intestines. They may be more research that has to be done to test the efficacy if animal derivatives are more potent as supposed to E.coli, but mass production means more availability and the accessibility to therapeutics that were previously difficult to reproduce, and in limited supply.